Effect of DVN therapy on production of NY-ESO-1 specific humoral and cellular immune responses
| Patient . | IPSS-R . | Best response . | Antibody response titer . | CD4 response . | CD8 response . | Post time point (ELISPOT) . | |||
|---|---|---|---|---|---|---|---|---|---|
| Base . | Post . | Base . | Post . | Base . | Post . | ||||
| 3DVN | Int | CR | - | - | – (0) | +++ (8) | – (0) | – (0) | Cycle 9, day 1 |
| 4DVN | Int | CR | - | - | – (0) | +++ (2) | – (0) | – (0) | Cycle 1, week 8 |
| 5DVN | High | SD | - | - | – (0) | + (2) | – (0) | – (0) | Cycle 9, day 1 |
| 6DVN | Very high | SD | - | - | – (0) | – (0) | – (0) | – (0) | Cycle 5, day 1 |
| 7DVN | Int | SD | - | - | – (0) | +++ (3) | – (0) | – (0) | Cycle 2, week 6 |
| 8DVN | Very high | SD | - | 20 075 | – (0) | NA | – (0) | – (0) | Cycle 4, day 15 |
| Patient . | IPSS-R . | Best response . | Antibody response titer . | CD4 response . | CD8 response . | Post time point (ELISPOT) . | |||
|---|---|---|---|---|---|---|---|---|---|
| Base . | Post . | Base . | Post . | Base . | Post . | ||||
| 3DVN | Int | CR | - | - | – (0) | +++ (8) | – (0) | – (0) | Cycle 9, day 1 |
| 4DVN | Int | CR | - | - | – (0) | +++ (2) | – (0) | – (0) | Cycle 1, week 8 |
| 5DVN | High | SD | - | - | – (0) | + (2) | – (0) | – (0) | Cycle 9, day 1 |
| 6DVN | Very high | SD | - | - | – (0) | – (0) | – (0) | – (0) | Cycle 5, day 1 |
| 7DVN | Int | SD | - | - | – (0) | +++ (3) | – (0) | – (0) | Cycle 2, week 6 |
| 8DVN | Very high | SD | - | 20 075 | – (0) | NA | – (0) | – (0) | Cycle 4, day 15 |
Patient number, IPSS-R, and best response are shown as in Table 1. Immune analyses were performed using peripheral blood samples collected at baseline (Base) and after the EOS (Post). NY-ESO-1 antibody levels were measured using enzyme-linked immunosorbent assay in patient sera. For patients 3DVN and 5-8DVN, assessment of posttreatment antibody titer was performed at cycle 5, day 1. For patient 4DVN, assessment of antibody titer was performed at cycle 1, week 8. Antibody response is displayed as reciprocal titer (negative [−] if reciprocal titer is <100). Frequencies of NY-ESO-1 antigen–specific T cells were measured using ELISPOT assays. Time points of post-EOS samples used in ELISPOT assays are shown. Responses were termed positive when the number of interferon gamma spots per 50 000 cells was twice that of the background level (unpulsed target cells; 21 spots): <25 spots (−); 25 to 99 spots (+); 100 to 199 spots (++); 200 to 499 spots (+++). Numbers in parentheses indicate the number of epitopes recognized by T cells.